8,882 Shares in AbbVie Inc. (NYSE:ABBV) Bought by MSH Capital Advisors LLC

MSH Capital Advisors LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 8,882 shares of the company's stock, valued at approximately $1,578,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Marshall Wace LLP increased its position in AbbVie by 18.6% in the 4th quarter. Marshall Wace LLP now owns 1,576,895 shares of the company's stock valued at $280,214,000 after buying an additional 247,726 shares in the last quarter. NewEdge Advisors LLC grew its position in AbbVie by 9.8% in the 4th quarter. NewEdge Advisors LLC now owns 497,253 shares of the company's stock valued at $88,362,000 after purchasing an additional 44,335 shares during the period. Main Street Financial Solutions LLC increased its stake in AbbVie by 4.7% during the 4th quarter. Main Street Financial Solutions LLC now owns 19,351 shares of the company's stock valued at $3,439,000 after purchasing an additional 862 shares in the last quarter. Stenger Family Office LLC acquired a new position in AbbVie during the fourth quarter worth $2,110,000. Finally, Lifelong Wealth Advisors Inc. bought a new position in shares of AbbVie in the fourth quarter valued at $246,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Performance

Shares of ABBV stock traded up $1.10 during trading on Friday, reaching $172.78. 8,474,425 shares of the company's stock traded hands, compared to its average volume of 6,005,419. AbbVie Inc. has a 1 year low of $153.58 and a 1 year high of $218.66. The firm's 50-day moving average is $198.47 and its 200 day moving average is $187.76. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. The company has a market capitalization of $305.64 billion, a P/E ratio of 71.99, a PEG ratio of 1.62 and a beta of 0.55.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same period in the prior year, the company posted $2.79 earnings per share. Equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be paid a $1.64 dividend. This represents a $6.56 annualized dividend and a yield of 3.80%. The ex-dividend date is Tuesday, April 15th. AbbVie's dividend payout ratio is presently 273.33%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ABBV shares. UBS Group upped their target price on shares of AbbVie from $181.00 to $190.00 and gave the stock a "neutral" rating in a report on Monday, February 3rd. Citigroup raised their target price on AbbVie from $205.00 to $215.00 and gave the company a "buy" rating in a report on Monday, February 3rd. Bank of America upped their price target on AbbVie from $200.00 to $223.00 and gave the stock a "neutral" rating in a report on Tuesday, March 4th. Truist Financial raised their price objective on AbbVie from $211.00 to $217.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Finally, Raymond James reiterated an "outperform" rating and issued a $220.00 target price (up previously from $218.00) on shares of AbbVie in a report on Monday, February 3rd. Seven research analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $210.71.

Insider Buying and Selling at AbbVie

In related news, EVP Perry C. Siatis sold 5,778 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $197.90, for a total value of $1,143,466.20. Following the transaction, the executive vice president now directly owns 22,381 shares in the company, valued at approximately $4,429,199.90. This represents a 20.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy J. Richmond sold 29,917 shares of AbbVie stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total transaction of $6,070,159.30. Following the sale, the executive vice president now directly owns 44,284 shares of the company's stock, valued at $8,985,223.60. This represents a 40.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 113,471 shares of company stock valued at $23,426,451 in the last three months. Company insiders own 0.25% of the company's stock.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.